OP Asset Management Ltd bought a new stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 28,977 shares of the medical instruments supplier’s stock, valued at approximately $4,556,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise increased its holdings in shares of Becton, Dickinson and Company by 1,275.2% during the first quarter. Banque Cantonale Vaudoise now owns 10,740 shares of the medical instruments supplier’s stock worth $1,688,000 after buying an additional 9,959 shares in the last quarter. Nautilus Advisors LLC grew its position in Becton, Dickinson and Company by 46.9% during the 1st quarter. Nautilus Advisors LLC now owns 2,115 shares of the medical instruments supplier’s stock worth $333,000 after acquiring an additional 675 shares during the last quarter. Cidel Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 22.6% in the 1st quarter. Cidel Asset Management Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $447,000 after purchasing an additional 524 shares in the last quarter. A. D. Beadell Investment Counsel Inc. raised its position in Becton, Dickinson and Company by 4.5% in the first quarter. A. D. Beadell Investment Counsel Inc. now owns 12,761 shares of the medical instruments supplier’s stock valued at $2,006,000 after purchasing an additional 551 shares during the last quarter. Finally, Webster Bank N. A. boosted its stake in shares of Becton, Dickinson and Company by 9.2% during the first quarter. Webster Bank N. A. now owns 2,606 shares of the medical instruments supplier’s stock valued at $410,000 after purchasing an additional 219 shares in the last quarter. 86.97% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the stock. Weiss Ratings lowered shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. TD Cowen lowered their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Evercore upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Finally, Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $181.00.
Becton, Dickinson and Company Price Performance
BDX stock opened at $156.06 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The company’s fifty day simple moving average is $148.17 and its 200 day simple moving average is $170.75. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The firm has a market cap of $43.00 billion, a price-to-earnings ratio of 39.51, a PEG ratio of 10.72 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the company posted $3.35 EPS. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 106.33%.
Insider Buying and Selling
In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock worth $765,120 over the last 90 days. Company insiders own 0.40% of the company’s stock.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
